Scancell cancer vaccine strategy backed by Moderna and Merck trial results

Panmure Liberum believes positive Phase 3 data for a cancer vaccine developed by Moderna and Merck supports the scientific rationale behind Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the cancer immunotherapy developer, and its lead melanoma treatment. Analysts Julie Simmonds and...